OWP-103

OWP-103 is an oral liquid formulation of trazodone hydrochloride under development by OWP Pharmaceuticals for the treatment of psychiatric disorders, specifically major depressive disorder (MDD). Developed via the 505(b)(2) regulatory pathway, OWP-103 is designed to provide an alternative, easy-to-swallow liquid dosage form for pediatric, geriatric, or other patients who experience dysphagia or difficulty swallowing traditional tablets. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that acts primarily as an antagonist at the serotonin 5-HT2A receptor and as an inhibitor of the serotonin transporter (SERT), while also exhibiting antagonistic activity at histamine H1 and alpha-1 adrenergic receptors.

Other names

trazodone hydrochloride oral liquidtrazodone oral liquidtrazodone oral solution